A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44

Cancer Immunol Immunother. 2007 Jun;56(6):753-9. doi: 10.1007/s00262-006-0244-5. Epub 2006 Nov 10.


A panel of cytolytic T lymphocyte (CTL) clones was isolated from metastases and blood samples of a melanoma patient vaccinated with MAGE-3.A1-pulsed autologous dendritic cells. We report here the identification of a new antigen encoded by the MAGE-C2 cancer-germline gene. This antigen is recognized by some of these CTL on HLA-B*4403. The sequence of the peptide is SESIKKKVL. It is processed in various melanoma cell lines expressing MAGE-C2 and HLA-B*4403. Because of the expression pattern of gene MAGE-C2, this new antigen is strictly tumor-specific and could therefore be used for peptide-based antitumoral vaccination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Antigen Presentation / immunology*
  • Antigens, Neoplasm / genetics*
  • Antigens, Neoplasm / immunology
  • COS Cells
  • Cancer Vaccines / therapeutic use
  • Chlorocebus aethiops
  • Clone Cells
  • Dendritic Cells / transplantation
  • HLA-B Antigens / immunology*
  • HLA-B44 Antigen
  • Humans
  • Melanoma / therapy
  • Molecular Sequence Data
  • Neoplasm Proteins / immunology*
  • Reverse Transcriptase Polymerase Chain Reaction
  • T-Lymphocytes, Cytotoxic / immunology*
  • Transfection


  • Antigens, Neoplasm
  • Cancer Vaccines
  • HLA-B Antigens
  • HLA-B44 Antigen
  • MAGEC2 protein, human
  • Neoplasm Proteins